Appendix 3B‌‌‌

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

New issue announcement, application for quotation of additional securities‌‌ and agreement‌

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

ANALYTICA LIMITED

ABN

12 006 464 866

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1

+Class of +securities issued or to be issued

  1. Fully Paid Ordinary Shares

  2. January Options (unlisted)

  3. May Options (unlisted)

2

Number of +securities issued or to be issued (if known) or maximum number which may be issued

In accordance with the renounceable pro rata entitlement offer (Entitlement Offer) announced to the market on 18 September 2017, the following equities have been issued from the shortfall:

(a) 3,000,000 shares;

  1. 3,000,000 January Options; and

  2. 3,000,000 May Options.

3

Principal terms of the

+securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if

+convertible securities, the conversion price and dates for conversion)

Shares

Fully paid ordinary shares.

January Options

January Options are exercisable at $0.005 per option expiring on 31 January 2018 and will not be listed.

May Options

May Options are exercisable at $0.005 per option expiring on 31 May 2018 and will not be listed.

4

Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

If the additional +securities do not rank equally, please state:

  • the date from which they do

  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Shares

The ordinary shares issued rank equally with all existing fully paid ordinary shares from the issue date.

Options

Shares will be issued on the exercise of the January Options and May Options and will rank equally with all other fully paid shares.

5

Issue price or consideration

$0.005 for each Share and attaching one January Option and one May Option.

6

Purpose of the issue

(If issued as consideration for the acquisition of assets, clearly identify those assets)

The capital raised from the allotment of shortfall shares will be used to fund development costs in connection with the PeriCoach System and general working capital purposes.

6a

Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

Yes

6b

The date the security holder resolution under rule 7.1A was passed

24 November 2016

6c

Number of +securities issued without security holder approval under rule 7.1

  1. 3,000,000 Entitlement Shares

  2. 3,000,000 January Options

  3. 3,000,000 May Options

6d

Number of +securities issued with security holder approval under rule 7.1A

Nil

6e

Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

Nil

6f

Number of +securities issued under an exception in rule 7.2

  1. 3,000,000 Entitlement Shares

  2. 3,000,000 January Options

  3. 3,000,000 May Options

6g

If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the

+issue date and both values. Include the source of the VWAP calculation.

N/A

6h

If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

N/A

6i

Calculate the entity's remaining issue capacity under rule

7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements

Rule 7.1 remaining capacity - 395,396,400 Rule 7.1A remaining capacity - 280,597,600

7

+Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

31 October 2017

Number

+Class

2,818,976,003

119,372,193

Ordinary Shares

Options - expiring

28 February 2018 at

1.4 cents

Number

+Class

Options

269,839,671

269,839,671

44,500,000

5,000,000

6,350,000

10,416,667

14,000,000

72,500,000

41,000,000

33,350,000

Options

Expiring 31/01/2018 at 0.5 cents

Expiring 31/05/2018 at 0.5 cents

Expiring 29/10/2018 at 3.22 cents

Expiring 12/02/2019 at 4.39 cents Expiring 22/05/2019 at 7.33 cents

Expiring 28/02/2020 at 1.9 cents

Expiring 9/12/2020 at

1.62 cents

Expiring 22/12/2021 at 1.3 cents

Expiring 8/6/2022 at

1.3 cents

Expiring 8/6/2022 at

1.036 cents

  1. Number and +class of all

    +securities quoted on ASX (including the +securities in section 2 if applicable)

  2. Number and +class of all

    +securities not quoted on ASX (including the +securities in section 2 if applicable)

    Unchanged

  3. Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Part 2 - Pro rata issue

11

Is security holder approval required?

12

Is the issue renounceable or non- renounceable?

13

Ratio in which the +securities will be offered

14

+Class of +securities to which the offer relates

15

+Record date to determine entitlements

Analytica Limited published this content on 31 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 31 October 2017 01:27:06 UTC.

Original documenthttp://www.analyticamedical.com/downloads/2017/20171031-ASX-ALT-Appendix3B.pdf

Public permalinkhttp://www.publicnow.com/view/E460559E673DAAFE71DC635CC8CC3E4AB04BDBB0